Compare FTCI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | ALXO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 79.7M |
| IPO Year | 2021 | 2020 |
| Metric | FTCI | ALXO |
|---|---|---|
| Price | $8.93 | $1.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $6.63 | $3.30 |
| AVG Volume (30 Days) | ★ 421.4K | 341.3K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,028,000.00 | N/A |
| Revenue This Year | $93.79 | N/A |
| Revenue Next Year | $165.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.53 | N/A |
| 52 Week Low | $2.13 | $0.40 |
| 52 Week High | $11.45 | $2.27 |
| Indicator | FTCI | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 45.25 |
| Support Level | $8.10 | $1.29 |
| Resistance Level | $9.70 | $1.56 |
| Average True Range (ATR) | 1.00 | 0.15 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 46.15 | 34.63 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.